PNAS: Heavy!

Non-alcoholic fatty liver (NAFLD, commonly known as fatty liver) is the most common chronic liver disease, affecting approximately 25% of adults
.

NAFLD includes non-alcoholic fatty liver (NAFL), as well as non-alcoholic steatohepatitis (NASH), fatty liver fibrosis, liver cirrhosis and so on

Non-alcoholic fatty liver (NAFLD, commonly known as fatty liver) is the most common chronic liver disease, affecting approximately 25% of adults

At present, the treatment of liver fibrosis is very limited
.

According to the US National Institutes of Health say, losing weight is the only known reduction associated with non-alcoholic fatty liver fibrosis method

At present, the treatment of liver fibrosis is very limited

 July 12, 2021 , published in "PNAS" "PNAS" , a study found , liver fibrosis may be designed to combine with mesothelin protein immunization to treat toxins

What is mesothelin ? Mesothelin is rarely found in healthy people
.

Only cancer cells and collagen-producing liver cells ( portal fibroblasts ) can make this protein

What is mesothelin ? Mesothelin is rarely found in healthy people

 Normal liver tissue (left) does not produce mesothelin, while the liver tissue of patients with primary sclerosing cholangitis does (right, darker staining)

In this study, in order to test Pastan's immunotoxin in the context of liver fibrosis, the researchers first needed an animal model

The results of the study found that compared with untreated mice, 60% to 100% of human mesothelin-producing cells were killed by immunotoxins, thereby reducing collagen deposition

In addition , anti-mesothelin immunotoxins are safe for humans, which may accelerate their clinical application

 References : Takahiro Nishio el al.

Leave a message here